The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes
Open accessAbstract
Purpose: Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) –related malignancy expressing EBV antigens that are possible targets of cell therapy, including latent membrane protein 2 (LMP2). We conducted a clinical trial of EBV-targeted cell therapy with autologous virus-specific cytotoxic T lymphocytes (CTLs) for NPC refractory to conventional treatments. Patients and Methods: Ten patients with EBV-related stage IV NPC in progression after conventional radiotherapy and chemotherapy received intravenously autologous EBV-specific CTLs reactivated and expanded ex vivo from peripheral blood lymphocytes through stimulation with EBV-transformed autologous B-lymphoblastoid cell lines (LCL). Toxicity, specific cellular immune responses, and clinical tumor responses were evaluated. Results: EBV-specific CTLs could be generated in all patients and were predominantly CD3+/CD8+ T lymphocytes displaying specific killing of autologous EBV-LCL, autologous NPC cells as well as autologous targets bearing the EBV antigen LMP2. Patients received two to 23 infusions of EBV-specific CTLs that were well tolerated with the exception of grade 1 to 2 inflammatory reactions at the tumor site in two cases. Control of disease progression was obtained in six of 10 patients (two with partial response and four with stable disease). Analysis of interferon-γ–producing cells demonstrated an increased frequency of EBV-specific immunity, with appearance of LMP2-specific responses in four patients, of whom three had clinical benefit. Conclusion: Cell therapy with EBV-targeted autologous CTLs is safe, induces LMP-2-specific immunologic responses, and is associated with objective responses and control of disease progression in patients with stage IV NPC resistant to conventional treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Cohen, J. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430707 · Cited by 1,636
Forastiere, A., Koch, W., Trotti, A., & Sidransky, D. (2001) · New England Journal of Medicine · doi:10.1056/nejmra001375 · Cited by 1,250
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
(2012) · SpringerReference · doi:10.1007/springerreference_301423 · Cited by 1,192
Thompson, M. P., & Kurzrock, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0670-3 · Cited by 786
HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTION
Rickinson, A. B., & Moss, D. J. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.405 · Cited by 747
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
Measuring Response in Solid Tumors: Unidimensional Versus Bidimensional Measurement
James, K., Eisenhauer, E., Christian, M., Terenziani, M., Vena, D., Muldal, A., & Therasse, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.523 · Cited by 401
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes
Straathof, K. C. M., Bollard, C. M., Popat, U., Huls, M. H., Lopez, T., Morriss, M. C., Gresik, M. V., Gee, A. P., Russell, H. V., Brenner, M. K., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2975 · Cited by 353
Lin, C. S., Lo, W.-F., Lee, T.-H., Ren, Y. L., Hwang, S., Cheng, Y.-F., Chen, C., Chang, Y.-S., Lee, S. P., Rickinson, A. B., et al. (2002) · PubMed · Cited by 220
Gottschalk, S., Edwards, O. L., Sili, U., Huls, M. H., Goltsova, T., Davis, A. R., Heslop, H. E., & Rooney, C. M. (2003) · Blood · doi:10.1182/blood-2002-05-1514 · Cited by 186
Savoldo, B., Huls, M. H., Liu, Z., Okamura, T., Volk, H., Reinke, P., Sabat, R., Babel, N., Jones, J. F., Webster-Cyriaque, J. Y., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0039 · Cited by 149
Taylor, G. S., Haigh, T. A., Gudgeon, N. H., Phelps, R. J., Lee, S. P., Steven, N. M., & Rickinson, A. B. (2003) · Journal of Virology · doi:10.1128/jvi.78.2.768-778.2004 · Cited by 132
Lee, S. P., Chan, A. T. �., Cheung, S., Thomas, W. A., Croom-Carter, D. S. G., Dawson, C., Tsai, C.-H. A., Leung, S. F., Johnson, P. J., & Huang, D. P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.573 · Cited by 126
Khanna, R., Moss, D. J., & Burrows, S. R. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01328.x · Cited by 112
Meij, P., Leen, A. M., Rickinson, A. B., Verkoeijen, S., Vervoort, M. B. H. J., Bloemena, E., & Middeldorp, J. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10309 · Cited by 111
Yang, J., Lemas, V. M., Flinn, I. W., Krone, C., & Ambinder, R. F. (2000) · Blood · doi:10.1182/blood.v95.1.241 · Cited by 107
Duraiswamy, J., Bharadwaj, M., Tellam, J., Connolly, G., Cooper, L. T., Moss, D. J., Thomson, S., Yotnda, P., & Khanna, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2196 · Cited by 81
Khanna, R. (1997) · International Immunology · doi:10.1093/intimm/9.10.1537 · Cited by 60
Whitney, B. M., Chan, A. T. �., Rickinson, A. B., Lee, S. P., Lin, C. K., & Johnson, P. J. (2002) · Journal of Medical Virology · doi:10.1002/jmv.10073 · Cited by 44
Cited by
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
Lee, A. W. M., Ma, B. B. Y., Ng, W. T., & Chan, A. T. C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9347 · Cited by 796
Review of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 756
Nasopharyngeal carcinoma: an evolving paradigm
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., King, A. D., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00524-x · Cited by 546
Metadata
- Authors
- Comoli, P., Pedrazzoli, P., Maccario, R., Basso, S., Carminati, O., Labirio, M., Schiavo, R., Secondino, S., Frasson, C., Perotti, C., Moroni, M., Locatelli, F., & Siena, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-10
- Volume
- 23
- Issue
- 35
- Pages
- 8942-8949
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096932117
- Cited by
- 289
- References
- 21
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.